A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients

Not Applicable

Completed

• Conditions: HIV Infections; Psoriasis

• Registration Number: NCT00002286
• Lead Sponsor: Glaxo Wellcome

Brief Summary

To evaluate the feasibility of Retrovir (AZT) in the treatment of psoriasis in HIV antibody positive patients. Retrovir has been shown to be effective in the treatment of AIDS. In addition, the administration of AZT appears to have induced a remission of psoriasis in one case study. In light of AZT's antiviral activity and potential effectiveness as an agent for the treatment of psoriasis, this would be the most likely treatment for HIV positive, psoriatic patients whose disease progresses quickly.

Detailed Description

Not available

Study Timeline

• Status Verified: 1989-09
• Study First Submitted: 1999-11-02
• Study First Submitted QC: 2001-08-30
• Study First Posted: 2001-08-31
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Glaxo Wellcome Inc; 🇺🇸 Research Triangle Park, North Carolina, United States